Cancer and genetic defects are examples of. “To End the Degeneration of a Nation”: Debates on Eugenic Sterilization in Inter-war Romania

The CLP Regulation makes sure that the hazards presented by chemicals are clearly communicated to workers and consumers in the European Union. The source of the information is mentioned in the introductory sentence of the hazard statements. When information is available in all sources, the first two are displayed as a priority.

Please note: The purpose of the information provided under this section is to highlight the substance hazardousness in a readable format. It does not represent a new labelling, classification or hazard statement, neither reflect other factors that affect the susceptibility of the effects described, such as duration of exposure or substance concentration e.

Other relevant information includes the following: Substances may have impurities and additives that lead to different classifications.

If at least one company has indicated that the substance classification is affected by impurities or additives, this will be indicated by an informative sentence. However, substance notifications in the InfoCard are aggregated independently of the impurities and additives.

Eugenic Sterilization as Medical Praxis

More help available here. Harmonised classification and labelling CLH Harmonised classification and labelling is a legally binding classification and labelling for a substance, agreed at European Community level. If the substance is covered by more than one CLH entry e.

• The degree of disability increases along with pathological damage, especially in cases with comorbidity.
• Giardia la copii tratament
• Gastric cancer ebv

It is possible that a harmonisation is introduced through an detoxifiere prin osmoza to the CLP Regulation. More info on CLH can be found here.

This information has not been reviewed or verified by ECHA, and may change without prior notice. These notifications can be provided by manufacturers, importers and downstream users. According to the harmonised classification and labelling ATP10 approved by the European Union, this substance may cause genetic defects, may cause cancer, causes damage to organs through prolonged or repeated exposure, is very toxic to aquatic life, is very toxic to aquatic life with long lasting effects, is harmful if swallowed, is harmful in contact with skin and is harmful if inhaled.

• In press Papers accepted for publication 1.
• Conspirații din paraziți umani, Tot felul de helminți în corpul uman
• Efecte secundare de vierme

Additionally, if available, cum se vindecă paraziții on the use of the substance and how consumers and workers are likely to be exposed to it can also be displayed here. The use information is displayed per substance life cycle stage consumer use, in articles, by professional workers widespread usesin formulation or re-packing, at industrial sites or in manufacturing.

The information is aggregated from the data coming from REACH substance registrations provided by industry. For a detailed overview on identified uses and environmental releases, please consult the registered substance factsheet.

Use descriptors are adapted from ECHA guidance to improve readability and may not correspond textually to descriptor codes described in Chapter R.

Translation of "cancer isn't hereditary" in Romanian

The examples provided are generic examples and may not apply to the specific substance you are viewing. A substance may have its use restricted to certain articles or products and therefore not all the examples may apply to the specific substance. Furthermore, some substances can be found in an article, but with unlikely exposure e.

The described Product category i. More help is available here.

“To End the Degeneration of a Nation”: Debates on Eugenic Sterilization in Inter-war Romania

This substance is used in articles, in formulation or re-packing, at industrial sites and in manufacturing. Consumer Cancer and genetic defects are examples of ECHA has no public registered data indicating whether or in which chemical products the substance might be used.

ECHA has no public registered data on the routes by which this substance is most likely to be released to the environment. Article service life Other release to the environment of this substance is likely to occur from: indoor use in long-life materials with low release rate e. This substance can cancer and genetic defects are examples of found in complex articles, with no release intended: electrical batteries and accumulators. Widespread uses by professional workers ECHA has no public registered data indicating whether or in which chemical products the substance might be used.

ECHA has no public registered data on the types of manufacture using this substance. Formulation or re-packing This substance is used in the following products: laboratory chemicals.

Release to the environment of this substance can occur from industrial use: formulation of mixtures.

Uses at industrial sites ECHA has no public registered data indicating whether or in which chemical cancer and genetic defects are examples of the substance might be used. This substance is used for the manufacture of: chemicals and electrical, electronic and optical equipment.

Release to the environment of this substance can occur from industrial use: in the production of articles and as an intermediate step in further manufacturing of another substance use of intermediates. Manufacture Release to the environment of this substance can occur from industrial use: manufacturing of the substance.

Recognised concerns are illustrated with a dark red icon.

There are no potential Ss or Sr s. Potential concerns are illustrated with a light red icon. Broad agreement concerns are illustratated with a solid outlined circle icon.

Minority position concerns are illustrated with a greyed out circle icon. Broad agreement: comes from industry data where a majority of data submitters agree the substance is carcinogenic. Minority position: comes from industry data where a minority of data submitters indicate the substance is carcinogenic.

More information about carcinogenicity here.

Broad agreement: comes from industry data where a majority of data submitters agree the substance is mutagenic. Minority position: comes from industry data where a minority of data submitters indicate the substance is mutagenic.

More information about mutagenicity here.

Broad agreement: comes from industry data where a majority of data submitters agree the substance is toxic to reproduction. Minority position: comes from industry data where a minority of data submitters indicate the substance is toxic to reproduction.

Directory of Research Journals Indexing

More information about reproductive toxicity here. Broad agreement: comes from industry data where a majority of data submitters agree the substance is a skin sensitiser. Minority position: comes from industry data where a minority of data submitters indicate the substance is skin sensitising. More information about skin sensitiser here.

Tot felul de helminți în corpul uman. Навигация по записям

Broad agreement: comes from industry data where a majority of data submitters agree the substance is a respiratory sensitiser. Minority position: comes from industry data where a minority of data submitters indicate the substance is a respiratory sensitiser. More information about respiratory sensitiser here. Broad agreement: comes from industry data where a majority of data submitters agree the substance is PBT.

Minority position: comes from industry data where a minority of data submitters indicate the substance is PBT. More information about persistent, bioaccumulative and toxic substances here.

At this time there is no explicit possibility for industry to indicate their opinion on ED status for substances. If and when this possibility exists it is proposed that industry data also be included in the ED property of concern calculation.

More information about endocrine disrupting substances here. The substance properties displayed in this section are derived from Harmonised classification and labelling CLH data, entries in the Candidate list of substances of very high concern for authorisationthe PBT assessment list, the ED assessment list, REACH registered dossier data and from notifications made under CLP.